Diffusion adds Isaac Blech to board of directors
Mr. Blech, an experienced biotechnology entrepreneur and investor, brings to Diffusion over 35 years of expertise in the biotech industry.
Mr. Blech has founded and served on the board of a number of companies that have produced major advances in a broad array of diseases, including the diagnosis of chlamydia, herpes, syphilis and HIV, and the treatment of cystic fibrosis, sexual dysfunction, multiple myeloma and many forms of cancer and hematological disease.
Among the companies he has established are Celgene Corporation, ICOS Corporation, purchased by Eli Lilly, Nova Pharmaceutical Corporation, Gliadel, purchased by Johnson & Johnson, Pathogenesis Corporation, purchased by Chiron, and Genetics Systems Corporation, later purchased by Bristol-Myers Squibb.
Among the boards Mr. Blech currently serves on are Cerecor, Inc., a CNS company, ContraFect Corporation, an infectious disease company, Medgenics, Inc., a biotechnology company, and Edge Therapeutics, Inc., a company that treats life-threatening neurological conditions. ■
LATEST MOVES FROM Virginia
- Freddie Mac appoints Stacey Goodman as CIO
- Performance Food Group appoints Kimberly S. Grant as director
- Gannett appoints Matthew Barzun to board
- Lumber Liquidators appoints Lee Reeves as SVP
- Leidos appoints Frank Kendall III to board
More inside POST